Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

计划入组 300 人 · 首次发布于 2022 年 12 月 5 日

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

计划入组 6 人 · 首次发布于 2022 年 2 月 21 日

Platform Trial Assessing Uptake, Safety and Efficacy of Theranostic Agents in Solid Tumors With Active Brain Metastases

计划入组 10 人 · 首次发布于 2025 年 9 月 17 日

Somatostatin

C₇₆H₁₀₄N₁₈O₁₉S₂ · Rx

somatostatin receptor subtype 5 antagonists

IL-1 receptor type 2 (Immunex)

Arvinas Estrogen Receptor, Inc.

United States

Arvinas Androgen Receptor, Inc.

United States

MEREO BIOPHARMA 2 LIMITED

United Kingdom

Perspective Therapeutics Advances [212Pb]VMT-α-NET Dose Escalation for Neuroendocrine Tumors

Perspective Therapeutics' \212Pb\-VMT-α-NET Shows Promise in Gastrointestinal Cancer Trial

Perspective Therapeutics Reports Sustained Tumor Response with Lead-212 Radiopharmaceutical in Neuroendocrine Tumors